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Abstract
Objective—To describe incidence of immune reconstitution inflammatory syndrome (IRIS) and 
its association with mortality in a large multisite US HIV-infected cohort applying an objective, 
comprehensive definition.
Design—We studied 2 610 patients seen during 1996–2007 who initiated or resumed highly 
active combination antiretroviral therapy (cART) and, during the next 6 months, demonstrated a 
decline in plasma HIV-RNA viral load of at least 0.5 log10 copies/ml or an increase of at least 
50% in CD4 cell count per microliter. We defined IRIS as the diagnosis of a type B or C condition 
[as per the Centers for Disease Control and Prevention (CDC) 1993 AIDS case definition] or any 
new mucocutaneous disorder during this same 6-month period.
Methods—We assessed the incidence of IRIS and evaluated risk factors for IRIS using 
conditional logistic regression and for all-cause mortality using proportional hazards models.
Results—We identified 370 cases of IRIS (in 276 patients). Median and nadir CD4 cell counts at 
cART initiation were 90 and 43 cells/μl, respectively; median viral load was 2.7 log10 copies/ml. 
The most common IRIS-defining diagnoses were candidiasis (all forms), cytomegalovirus 
infection, disseminated Mycobacterium avium intracellulare, Pneumocystis pneumonia, varicella 
zoster, Kaposi’s sarcoma and non-Hodgkin lymphoma. Only one case of Mycobacterium 
tuberculosis was observed. IRIS was independently associated with CD4 cell count less than 50 
cells/μl vs. at least 200 cells/μl [odds ratio (OR) 5.0] and a viral load of at least 5.0 log10 copies vs. 
less than 4.0 log10 copies (OR 2.3). IRIS with a type B-defining or type C-defining diagnosis 
approximately doubled the risk for all-cause mortality.
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Conclusion—In this large US-based HIV-infected cohort, IRIS occurred in 10.6% of patients 
who responded to effective ART and contributed to increased mortality.
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HAART; HIV; immune reconstitution inflammatory syndrome; mortality; opportunistic 
infections; risk factors; United States
Introduction
Treatment of HIV infection usually results in a variable degree of immune reconstitution 
accompanied by a reduction in the risk of opportunistic infections. In some instances, 
however, a paradoxical worsening of an existing opportunistic infection or the emergence of 
a new opportunistic infection can occur after initiation of antiretroviral therapy (ART). This 
type of event, termed immune reconstitution inflammatory syndrome (IRIS), has been 
reported most commonly in association with mycobacterial infections [Mycobacterium 
tuberculosis infection (TB) and disseminated Mycobacterium avium complex (MAC)] [1,2], 
but has also been reported with many other opportunistic infections, including those caused 
by fungi (e.g., Pneumocystis pneumonia (PCP), toxoplasmosis, coccidioidomycosis], viruses 
[e.g., hepatitis B virus (HBV) and hepatitis C virus (HCV), cytomegalovirus (CMV) 
infection, varicella zoster virus (VZV), progressive multifocal leukoencephalopathy], and 
parasites (e.g. leishmaniasis). An event has typically been considered IRIS, and not a new 
opportunistic infection, if it occurs within the first 4–8 weeks of ART initiation; however, 
events attributed to IRIS have occurred later [3-10] (reviewed in [11-14]). With the 
exception of IRIS in the context of TB [15], there has been no unifying definition with 
which to describe this entity and define its scope. Reports have varied both in definition of 
immune reconstitution and the scope of conditions considered related to this event. As a 
result, comparisons of the incidence and risk factors for IRIS across reports are difficult. 
Using data from a large, long-standing, and well characterized prospective cohort of HIV-
infected adults, we explored IRIS incidence, risk factors, and consequences using a broad 
definition of IRIS that could be standardized for comparative reporting. We included as 
IRIS-defining events all AIDS-defining illnesses and a series of HIV-related and other (e.g. 
autoimmune) conditions previously reported in association with recovery of immune 
function during ART.
Methods
The HIV Outpatient Study
The HIV Outpatient Study (HOPS) is an open, prospective cohort study of HIV-infected 
patients seen at 10 university and private HIV specialty clinics in eight US cities since 1993 
[16]. Patient data, including socio-demographic characteristics and all diagnoses, treatments, 
and laboratory values, are abstracted from medical charts and entered into an electronic 
database for central processing and analysis. All HOPS clinicians have extensive experience 
treating HIV-infected patients. Since its inception, the HOPS protocol has been reviewed 
annually and approved by the Centers for Disease Control and Prevention (CDC) (Atlanta, 
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Georgia, USA), Cerner Corporation (Vienna, Virginia, USA), and each local site’s 
institutional review board; all participants have provided written, informed consent.
Study population and inclusion criteria
We included HOPS patients who between 1 January 1996 and 31 December 2007 were 
antiretroviral-naive and initiated highly active combination ART (cART, defined below); 
receiving antiretrovirals in a regimen that did not qualify as cARTand changed to a 
cARTregimen; or virologically failing or discontinued a cART regimen and started a new 
cARTregimen. Rather than requiring a minimum follow-up period (e.g. 180 days), which 
might have excluded IRIS events occurring before the minimum observation period had 
elapsed, we instead required each patient to have viral load values recorded at baseline and 
on at least one occasion during the initial 180 days of follow-up to show evidence of an 
adequate response to cART, defined as either a 0.5 log10 copies/ml or greater decrease in 
viral load within 6 months after initiating a new or different cART regimen or, in the 
absence of sufficient viral load reduction, by a 50% or greater increase in CD4 cell count 
during this same period. These criteria applied to both those who did and did not develop an 
IRIS-related condition.
Definitions of predictor variables
We defined cART per standard criteria [16]. Baseline was defined as the date a new or 
different cART regimen was initiated. Baseline plasma HIV-RNA viral load and CD4 cell 
count were defined as the values closest to the start of this regimen within the preceding 180 
days; patients lacking these data were excluded. Follow-up values for plasma HIV-RNA and 
CD4 cell count were taken as the measurements that occurred within the first 180 days after 
the start of cART regimen and prior to the end of the regimen.
Chronic co-infection with HBV or HCV (not considered IRIS-defining events) was defined 
based on a positive value for any of the following tests performed any time prior to baseline 
and up to 180 days thereafter: HBV surface antigen, HBVe antigen, quantitative or 
qualitative HBV or HCV plasma viral load, HCV antibody, or HCV genotype (i.e., type 
specified). Mycobacterium tuberculosis exposure was defined as a diagnosis of TB, a 
positive TB skin test, or a positive interferon-γ release assay any time prior to baseline and 
up to 7 days thereafter.
Definitions of outcome variable
In addition to IRIS with a type B-defining or type C-defining diagnosis (per 1993 
surveillance case definition for AIDS) [17], we included select autoimmune disorders and 
mucocutaneous conditions (see below) not otherwise classified as type B or C, but reported 
as associated with IRIS in the literature or by extrapolation might possibly be associated 
with IRIS. Accordingly, we defined a case of IRIS as a patient who developed type B or C 
illness [17], an autoimmune disorder, or a mucocutaneous condition not otherwise classified 
as type B or C between 7 and 180 days after initiating the qualifying cART regimen. Our 
initial list of diagnoses of autoimmune disorders that were IRIS-defining was broadly 
inclusive: Crohn’s disease, idiopathic thrombocytopenic purpura, Grave’s disease, 
Hashimoto’s thyroiditis, systemic lupus erythematosis, sarcoidosis, Sjogren’s syndrome, 
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myasthenia gravis, Raynaud’s disease, rheumatoid arthritis, Addison’s disease, Guillian–
Barre syndrome, pernicious anemia, Wegener’s granulomatosis, vitiligo, or ankylosing 
spondylitis. We also included in the outcome definition new diagnoses of any of the 
following mucocutaneous conditions not otherwise classified as type B or C: anogenital 
Herpes simplex virus infection, condylomata, folliculitis, tinea at any site, and molluscum 
contagiosum, all previously reported as conditions thought to be associated with IRIS 
[18-20]. We analyzed all IRIS events combined and then separately type B and C vs. 
mucocutaneous conditions. Diagnoses were defined as recurrent if 90 days had passed 
between the end date of the diagnosis’ first occurrence and the start of its second occurrence. 
Diagnoses recurring fewer than 90 days from the stop date of a prior occurrence were not 
included. We restricted analyses of IRIS to conditions that were diagnosed after initiation of 
cART (i.e. not apparent at the time of cART initiation). We did not evaluate episodes of 
paradoxical worsening of a preexisting opportunistic infection after initiation of cART due 
to lack of existing standardized data in the HOPS to quantify if the severity of a condition 
worsened. For wasting (≥10% weight loss), we calculated each patient’s percentage weight 
change between their heaviest weight measured in the year prior to baseline and their 
subsequent weight measured following initiation of cART. We used wasting to define a case 
of IRIS only in those cases in which no other IRIS-defining events were present.
Analysis methods
For estimating incidence of IRIS, patients who experienced IRIS contributed person-years of 
observation (pyo) from the time of initiating the qualifying cART regimen to the date of the 
IRIS-defining diagnosis, which by definition occurred within the first 6 months of therapy. 
Patients who did not experience IRIS contributed pyo from the time of initiating the 
qualifying cART regimen to the date 6 months later; regimens of shorter duration were 
censored at their end date. Individual patients could contribute pyo from multiple qualifying 
cART regimens and, therefore, more than one IRIS event. The denominator equaled the sum 
of pyo contributed by all patients meeting the inclusion criteria. The numerator equaled the 
sum of IRIS cases observed. We assessed crude differences in time to IRIS by type of IRIS 
event, and time from baseline to death for patients who did and did not experience IRIS, 
using the Wilcoxon rank-sum test.
We also conducted a case-control analysis to further assess risk factors for IRIS. Cases and 
controls were matched on the year a qualifying cART regimen was started and on ART 
status (naive vs. experienced) at the start of that regimen. We randomly selected four 
controls for each IRIS case, using incidence density sampling methodology. In our 
multivariable conditional logistic regression models, we included all factors explored in 
univariate analyses: viral load and CD4 cell count, HIV transmission risk group, race/
ethnicity, age, sex, hepatitis co-infection status, and history of TB exposure (e.g. positive 
skin test) or known TB infection.
Finally, we investigated whether IRIS was associated with increased mortality in our study 
cohort using Cox proportional hazards analyses. The start of observation was the start date 
of the qualifying cART regimen during which a patient developed first IRIS event; it was 
the start of the first qualifying cART regimen for patients who did not develop any IRIS 
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events. The end of observation was either last HOPS contact, date of death, or 31 March 
2008. We analyzed deaths documented within 180 days of last HOPS contact; patients not 
known to have died in that period were assumed alive.
All analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina, 
USA).
Results
Among 8 712 HOPS patients in the HOPS database as of 31 March 2008, we identified 2 
610 patients meeting criteria for analyses. This study population included 81.0% men, 
41.5% patients of nonwhite race/ethnicity, and 30.5% patients who were antiretroviral-naive 
[median age (interquartile range, IQR) at first qualifying cART: 40 (35, 46) years, median 
nadir CD4 cell count: 187 (54, 320) cells/μl].
The 2 610 patients contributed 3 557 qualifying cART regimens to analyses of IRIS rates. 
During follow-up, IRIS was documented during 370 (10.4%) cART regimens and affected 
276 (10.6%) of 2 610 patients (Table 1). One hundred and seventy-two (46.5%) of the 370 
cases of IRIS were type B or C events, affecting 6.6% of patients; 198 (53.5%) events were 
mucocutaneous manifestations, and there were no autoimmune disorders other than 
idiopathic thrombocytopenic purpura, which was already captured as type B event. There 
were 28 patients with multiple IRIS events.
Candidiasis of any type was the most common IRIS-defining event (Table 2). Other 
common IRIS events were CMV end-organ disease, MAC, and PCP. Common 
mucocutaneous events not otherwise classified as type B or C included anogenital Herpes 
simplex, condylomata, folliculitis, tinea, and molluscum contagiosum. The median time 
from the start of the qualifying cART regimen to an IRIS event was 63 days (range: 7–170, 
IQR: 28–120): for the 81 type B events, median 65 days (range: 8–169, IQR: 31–132), for 
the 91 type C events, median 40 days (range: 8–161, IQR: 17–92), and for the 198 
mucocutaneous events, median 73 days (range: 7–170, IQR: 35–122) (P < 0.001 for 
difference by type of event).
Overall, the incidence of IRIS by our definition was 25.1 per 100 pyo (Table 3), and it was 
higher for patients with lower baseline CD4 cell count and with higher baseline viral load. 
Incidence of IRIS type B and C events only (i.e., excluding mucocutaneous events) was 12.0 
per 100 pyo [with 95% confidence interval (CI): 10.4, 13.9].
In univariate conditional logistic regression analyses, development of IRIS was associated 
(P < 0.05) with female sex; nonwhite race/ethnicity; IDU or heterosexual risk category 
compared with MSM; baseline viral load at least 4 log10 copies/ml; and baseline CD4 cell 
count below 200 cells/μl; whereas age of 50 years and older was protective against 
developing IRIS (Table 4). In analyses limited to type B and C events, in addition to 
stronger associations with low CD4 cell count and high viral load, HCV or HBV infection 
was also associated with increased odds of IRIS (supplemental on-line Table 4a, http://
links.lww.com/QAD/A202). For mucocutaneous events, factors associated with IRIS on 
univariate analyses included nonwhite race/ethnicity, heterosexual risk category, baseline 
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viral load at least 5 log10 copies/ml and baseline CD4 cell count less than 200 cells/μl 
(supplemental on-line Table 4b, http://links.lww.com/QAD/A202).
In multivariable analyses, the odds of any IRIS event were 2.3 times as high among patients 
with a baseline viral load at least 5 log10 copies/ml compared with baseline viral load less 
than 4 log10 copies/ml and 5.0 and 2.2 times as high among those with baseline CD4 cell 
counts less than 50 and 50–199 cells/μl, respectively, compared with those with baseline 
CD4 cell counts of at least 200 cells/μl (Table 4). Patients who were heterosexual or of 
nonwhite race also had higher odds of IRIS. In analyses limited to type B and C IRIS events, 
the adjusted associations with low CD4 cell count and high viral load were even stronger, 
whereas there was less evidence for association with HBV or HCV (supplemental Table 4a, 
http://links.lww.com/QAD/A202). For mucocutaneous events, these associations remained 
and age at least 35 years was also protective (supplemental Table 4b, http://
links.lww.com/QAD/A202).
Among the 2 610 patients included in the analyses, we observed 263 deaths: 64 deaths 
among 276 patients who experienced IRIS, 199 deaths among those who did not. Among 
patients who died, the median time from baseline to death was 40.6 months (IQR: 19.2–
90.2) and 53.1 months (IQR: 23.2–95.5), respectively, for persons who did vs. did not 
experience IRIS-defining events (P = 0.009). In univariate proportional hazards analyses, 
the mortality was significantly higher after the occurrence of a type B or type C IRIS event, 
but was not associated with mucocutaneous events (Table 5). Other baseline factors 
associated with mortality in univariate analysis included non-Hispanic black or Hispanic 
race/ethnicity, age more than 40 years, IDU history, viral load more than 5 log10 copies/ml, 
low CD4 cell count, a history of an AIDS-defining diagnosis, initiation of cART between 
1996 and 2000, having public or other insurance (compared with private), and prior 
antiretroviral experience (Table 5). After adjusting for these covariates in multivariable 
analysis, type B and C IRIS events remained significantly associated with mortality (hazard 
ratios 2.3 and 2.4, respectively), whereas mucocutaneous events were associated with a 
reduced risk of mortality (hazard ratio 0.54, 95% CI: 0.32, 0.92, Table 5).
In sensitivity analyses, restricted to 1 518 patients who experienced suppression of viral load 
less than 1000 copies/ml on their first qualifying cART regimen (this viral load limit was 
chosen to account for the range of sensitivities of the various viral load assays used over the 
period of study), the incidence rate of IRIS (n = 122 events) was 18.7 per 100 pyo (95% CI: 
15.6, 22.2) and was not statistically different for patients who were baseline antiretroviral-
naive vs. antiretroviral-experienced (data not shown). In the same subset of patients, type C 
events remained associated with increased mortality in analyses controlling for viral load, 
CD4 cell count, and age (hazard ratio: 3.3, 95% CI: 1.6, 6.8); type B or mucocutaneous 
events were not associated with survival in this smaller subset of patients who experienced 
virologic suppression.
Discussion
We have developed a definition for IRIS that is broader than those used in earlier 
descriptions of this entity and have applied it to a substantially larger observational cohort 
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than previous studies. Broadening the definition to include type B and C events and 
mucocutaneous conditions increased the percentage of affected patients from 6.6 to 10.6%. 
The incidence of IRIS, using this broad inclusive definition, is lower than that in prior 
smaller cohort studies from single institutions in industrialized countries, some of which 
focused on subsets of opportunistic infections or included subgroups with demographic 
profiles more consistent with a developing country [2,5,21]. Our observed incidence may be 
lower for a number of reasons. First, although we and others observed that risk for IRIS was 
increased among persons with low CD4 cell count and elevated viral load, over 50% of 
the ’qualifying cART regimens’ in our analyses had baseline CD4 cell count at least 200 
cells/μl and more than one-fifth had baseline viral load less than 10 000 copies/ml. Using the 
large HOPS dataset, we were able to demonstrate that the incidence of IRIS varies by 
baseline CD4 cell count, which may explain the higher rates reported in prior studies 
focused on persons with CD4 cell count less than 200 cells/μl. Second, prevalence of TB in 
the United States is vastly lower than that in other regions where it is both a major AIDS-
defining condition and IRIS-defining condition. Finally, and perhaps most important, our 
definition of an IRIS-defining event, in contrast to some previous studies, did not include 
paradoxical worsening of an existing condition. The nature of our data source (chart 
abstraction of diagnoses and laboratory values), like many observational HIV cohort studies, 
did not permit reliable characterization of the course of disease or change in the quality of 
illness.
The HOPS draws patients only from the United States, reflecting HIV-related conditions 
more often seen in industrialized countries. As a result, it is not surprising that 
mycobacterial diseases, and particularly TB, were rare as IRIS events in our cohort, whereas 
candidiasis was the preponderant event. In observational cohorts from Africa and Asia, TB 
is consistently the most common IRIS-related event [22-25]. In the largest such study to date 
among 423 treatment-naive South Africans, 44 (10.4%) patients developed IRIS for an 
incidence rate of 25.1 cases per 100 pyo, with 18 patients developing tuberculosis [22]. In a 
prospective study from Ethiopia among 186 HIV-infected patients, with a mean CD4 cell 
count of 123 cells/μl, and in whom more than 60% had an opportunistic infection prior to or 
at the time of initiation of cART, 32 (17.2%) patients experienced IRIS, including 22 who 
developed TB [23].
Our study contributes to the available evidence that IRIS-related events may fall outside the 
CDC case definition for HIV-associated and AIDS-defining events. These diagnoses have 
included oral manifestations such as parotid enlargement or candidiasis [26,27] and 
autoimmune diseases, such as autoimmune hepatitis [28], ulcerative colitis [29], sarcoidosis 
[30], Grave’s disease [31], and Reiter’s syndrome [32]. Only one such event was seen in the 
HOPS cohort. Skin manifestations such as molluscum contagiosum [20], cutaneous warts 
[19], herpes zoster [33], and genital herpes simplex virus [5,34] have also been observed as 
IRIS events. In the developing world, entities such as leprosy [35-37] and leishmaniasis 
[2,3,38] have also been observed.
A novel finding of our study was the striking association of having experienced an IRIS-
defining event with an increased risk of death, after adjusting for baseline CD4 cell count. A 
similar result was observed in a small Mexican cohort, but differs from a South Korean 
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report that found no association of IRIS with mortality [39,40], potentially due to small 
sample size, shorter duration of follow-up, and differences in the definition of IRIS. In our 
study, the association between IRIS and increased mortality was evident for both HIV-
associated and generally nonlife-threatening (type B) events as well as AIDS-defining and 
potentially life-threatening events (type C), but was not apparent for mucocutaneous events. 
Indeed, although mucocutaneous events were not associated with mortality in crude analyses 
(hazard ratio 0.99), they appeared to be protective for mortality after adjusting for CD4, viral 
load, and other factors. Most mucocutaneous events are not life threatening and would not 
be expected to contribute to death, and the appearance of a protective association in adjusted 
analyses is somewhat surprising and needs to be interpreted cautiously. Whether the 
mucocutaneous events should be included in the definition of IRIS is less important than to 
understand that their occurrence carries less clinical significance. We could not establish the 
relative contributions of individual type B and C events to mortality due to the relatively 
small number of events observed.
Our study is subject to several additional limitations. Diagnoses of some opportunistic 
infections in the HOPS do not require laboratory confirmation and some IRIS-defining 
events could, thus, have been misclassified. As with all observational data, we could not 
exclude the possibility of residual and unmeasured confounding (e.g. type of cART, 
adherence to prescribed ART) that might have affected the conclusions. We note that our 
inclusion criteria were based on virologic and immunologic responses to a new cART 
regimen regardless of its antiretroviral composition or patient adherence. Analyses using 
data from other large cohort studies to examine risk factors associated with IRIS and the 
potential contribution of IRIS to mortality could be helpful in determining whether the 
associations we observed are valid and generalizable. Further, the diagnoses we considered 
as IRIS-defining included only conditions endemic to North America and specifically the 
United States; the distribution of IRIS-defining events and their individual incidence rates 
likely differ in other regions where characteristics of patients initiating cART and 
prevalence of opportunistic infections may differ substantially. In our study, we did not 
evaluate episodes of worsening of a preexisting opportunistic infection after cART initiation 
(i.e., paradoxical IRIS), because we could not apply standardized criteria for ‘worsening’ of 
a condition based solely on review of existing medical records. As noted earlier, this 
limitation may explain why the incidence of IRIS we observed was relatively low compared 
with some smaller studies in the United States and Europe [2,5,21].
Little is known about the pathophysiologic mechanisms for IRIS. Elevated serum pro-
inflammatory biomarkers have been observed both before and after cART initiation in 
patients who subsequently developed IRIS, findings consistent with the inflammatory nature 
of the syndrome [41,42]. Some data suggest a role for T-regulatory cells (Tregs) [43]. The 
observed association of HCV or HBV co-infection with IRIS that was seen in univariate 
analyses, limited to type B and C events, but that was less apparent in multivariable analysis 
was unexpected. The effect of chronic viral hepatitis on Treg function may contribute to 
dysregulation of immune recovery, which could contribute to the emergence of IRIS 
[44,45]. The implication that co-infections may selectively impact overlapping immune 
mechanisms for the emergence of IRIS must also be considered in understanding this 
phenomenon.
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In conclusion, as others have observed, we found that IRIS was associated with low CD4 
cell count and high viral load at the time of effective cART initiation or resumption. A novel 
association of IRIS-defining type B and C events with increased risk for subsequent 
mortality, if supported by other research, might provide another compelling reason for 
earlier cART initiation. Research to identify the biological mechanisms underlying IRIS 
may facilitate earlier identification of persons at risk for the condition, as well as effective 
interventions to prevent it.
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Table 1
Characteristics of 2610 patients followed after initiating 3557 qualifying combination 
antiretroviral therapy regimens who did and did not develop immune reconstitution 











n (%) P value
a
Age (years) 0.072
 18–34 859 (24.2) 104 (28.1) 755 (23.7)
 35–49 2146 (60.3) 220 (59.5) 1926 (60.4)
 50+ 552 (15.5) 46 (12.4) 506 (15.9)
Sex 0.95
 Female 726 (20.4) 76 (20.5) 650 (20.4)
 Male 2831 (79.6) 294 (79.5) 2537 (79.6)
Race/ethnicity 0.007
 White, non-Hispanic 2018 (56.7) 180 (48.7) 1838 (57.7)
 Black, non-Hispanic 1051 (29.6) 127 (34.3) 924 (29.0)
 Hispanic 374 (10.5) 51 (13.8) 323 (10.1)
 Other/unknown 114 (3.2) 12 (3.2) 102 (3.2)
HIV transmission risk group 0.18
 MSM 2142 (60.2) 207 (56.0) 1935 (60.7)
 IDU 394 (11.1) 48 (13.0) 346 (10.9)
 Heterosexual 819 (23.0) 97 (26.2) 722 (22.7)
 Other/unknown 202 (5.7) 18 (4.9) 184 (5.8)
CD4 cell count category (cells/μl) <0.001
 <50 557 (16.7) 137 (41.0) 420 (14.0)
 50–199 905 (27.1) 93 (27.8) 812 (27.0)
 ≥200 1881 (56.3) 104 (31.1) 1777 (59.1)
HIV viral load (log10copies/ml) <0.001
 <4 762 (21.4) 44 (11.9) 718 (22.5)
 4-<5 1491 (41.9) 115 (31.1) 1093 (34.3)
 ≥5 1304 (36.7) 211 (57.0) 1093 (34.3)
HCV co-infection 0.34
 Yes 490 (13.8) 45 (12.2) 445 (14.0)
 No 3067 (86.2) 325 (87.8) 2742 (86.0)
HBV co-infection 0.63
 Yes 172 (4.8) 16 (4.3) 156 (4.9)
 No 3385 (95.2) 354 (95.7) 3031 (95.1)
TB exposure
 Yes 156 (4.4) 20 (5.4) 136 (4.3) 0.31
 No 3401 (95.6) 350 (94.6) 3051 (95.7)
HBV, hepatitis B virus;HCV, hepatitis C virus; IRIS, immune reconstitution inflammatory syndrome;TB, tuberculosis.
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a
P value determined using the χ2-test.
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Table 2
Frequency of immune reconstitution inflammatory case-defining events in HIV 
Outpatient Study, United States, 1996–2007 (N = 370)
IRIS-defining condition N %
Type of
condition
Candidiasis, any 85 23.0 -
 Oral 64 17.3 B
 Esophageal 15 4.1 C
 Vaginal 6 2.0 MC
Folliculitis 51 13.8 MC
Herpes simplex infection, any 37 12.4 -
 Genitourinary 21 5.7 MC
 Anorectal 16 4.3 MC
Condyloma, any 45 12.2 MC
 Genitourinary 27 7.3 MC
 Anorectal 18 4.9 MC
Tinea 41 11.1 MC
Molluscum contagiosum, any 24 6.5 MC
 Cutaneous 23 6.2 MC
 Genitourinary 1 0.3 MC
Mycobacterial disease, any 15 4.1 -
 Disseminated Mycobacterium
  avium complex
12 3.2 C




Cytomegalovirus infection, any 13 3.5 C
 Colonic 4 1.1 C
 Retinal 5 1.4 C
 Esophagitis 1 0.3 C
 Other 3 0.8 -
Pneumocystis pneumonia 10 2.7 C
Kaposi’s sarcoma, any 9 2.4 C
 Cutaneous 8 2.2 C
 Gastrointestinal 1 0.3 C
Zoster 9 2.4 B
Non-Hodgkin’s lymphoma 8 2.2 C
Wasting syndrome 6 1.6 C
Cryptococcal disease, any 4 1.1 C
 Meningitis 2 0.5 C
 Systemic 2 0.5 C
Toxoplasmosis 3 0.8 C
Cryptosporidiosis 3 0.8 C
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IRIS-defining condition N %
Type of
condition
Histoplasmosis 2 0.5 C







Conditions presented in order of decreasing frequency of the main category. B and C represents type B-defining or type C-defining diagnoses (per 
1993 surveillance case definition for HIV/AIDS). IRIS, immune reconstitution inflammatory; MC, mucocutaneous condition.













Novak et al. Page 17
Table 3
Incidence of immune reconstitution inflammatory among persons after initiating 
qualifying combination antiretroviral therapy regimens
a
, by select patient characteristics, 







100 pyo (95% CI)
Overall 370 1474.2 25.1 (22.6, 27.8)
ART experience
 Naive 91 336.4 27.1 (21.8, 33.2)
 Experienced 279 1137.8 24.5 (21.7, 27.6)
CD4 category (cells/μl)
 <50 137 197.5 269.4 (58.2, 82.0)
 50–99 33 123.9 26.6 (18.3, 37.4)
 100–199 60 245.4 24.4 (18.7, 31.5)
 200–349 57 400.7 14.2 (10.8, 18.4)
 ≥350 47 418.5 11.2 (8.3, 14.9)
VL category (log10copies/ml)
 <3 13 97.0 13.4 (7.1, 22.9)
 3–< 4 31 235.2 13.2 (9.0, 18.7)
 4–< 5 115 631.5 18.2 (15.0, 21.9)
 5–< 6 198 491.4 40.3 (34.9, 46.3)
 ≥6 13 19.1 68.1 (36.2, 116.4)
Year qualifying cART regimen started
 1996–1997 106 372.4 28.5 (23.3, 34.4)
 1998–1999 79 276.0 28.6 (22.7, 35.7)
 2000–2001 66 243.0 27.2 (21.0, 34.6)
 2002–2003 44 232.7 18.9 (13.7, 25.4)
 2004–2005 50 219.2 22.8 (16.9, 30.1)
 2006-2007 25 130.9 19.1 (12.4, 28.2)
An adequate response to cART was defined as either a ≥0.5 log10copies/ml decrease in HIV-RNA viral load within 6 months after initiating a new 
or different cART regimen, or in the absence of sufficient viral load reduction, by a 50% increase in CD4 cell count during this same time period. 
ART, antiretroviral therapy; cART, combination ART; IRIS, immune reconstitution inflammatory; VL, HIV viral load.
a
For 2610 patients, incidence of IRIS on 3 557 qualifying cART regimens was analyzed.
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Table 4
Factors associated with immune reconstitution inflammatory in case-control conditional 
logistic regression univariate and multivariate models in the HIV Outpatient Study, 
United States, 1996–2007 (N = 1 850)
Baseline factors OR (95% CI) P value Adjusted OR (95% CI) P value
Age (years)
 35–49 0.82 (0.63, 1.07) 0.14 0.68 (0.49, 0.95) 0.022
 50+ 0.65 (0.44, 0.95) 0.028 0.66 (0.42, 1.05) 0.076
 18–34 Referent Referent
Sex
 Female 1.72 (1.27, 2.33) <0.001 0.93 (0.58, 1.50) 0.77
 Male Referent Referent
Race/ethnicity
 White, non-Hispanic Referent Referent
 All other 2.45 (1.93, 3.10) <0.001 1.50 (1.11, 2.03) 0.009
HIV risk group
 IDU 2.50 (1.70, 3.68) <0.001 1.63 (0.96, 2.77) 0.069
 HRH 2.21 (1.67, 2.92) <0.001 1.63 (1.03, 2.56) 0.036
 Other/unknown 1.34 (0.78, 2.31) 0.29 0.69 (0.35, 1.36) 0.29
 MSM Referent Referent
CD4 cell count (cells/μl)
a
 <50 7.60 (5.44, 10.60) <0.001 5.01 (3.46, 7.27) <0.001
 50–199 2.57 (1.87, 3.54) <0.001 2.15 (1.54, 3.02) <0.001
 ≥200 Referent Referent
HIV viral load (log10copies/ml)
a
 <4 Referent Referent
 4-<5 1.46 (1.00, 2.14) 0.050 1.32 (0.85, 2.04) 0.22
 ≥5 3.73 (2.58, 5.38) <0.001 2.33 (1.51, 3.61) <0.001
HCV or HBV co-infection
 Yes 1.38 (0.997, 1.90) 0.052 1.16 (0.76,1.74) 0.49
 No Referent Referent
TB exposure
 Yes 1.40 (0.82, 2.36) 0.22 0.96 (0.52,1.80) 0.90
 No Referent Referent
CI, confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; HRH, high-risk heterosexual; OR, odds ratio; TB, tuberculosis.
a
Viral load and CD4 cell count values closest to the start of a new or different combination antiretroviral therapy within the preceding 180 days.
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Table 5
Factors associated with mortality among patients demonstrating an adequate response to 
combination antiretroviral therapy in the HIV Outpatient Study, United States, 1996–
2007 (N = 2 610)
Baseline factor
Univariate analysis
HR (95% CI) P value
Adjusted analysis
HR (95% CI) P value
Any IRIS (B, C, mucocutaneous)
 IRIS diagnosis 2.38 (1.80, 3.14) <0.001 NA
 No IRIS diagnosis
IRIS stratified
 Type C diagnosis 4.69 (3.15, 6.96) <0.001 2.39 (1.58, 3.61) <0.001
 Type B diagnosis 4.28 (2.70, 6.79) <0.001 2.29 (1.43, 3.67) <0.001
 Mucocutaneous diagnosis 0.99 (0.59, 1.64) 0.96 0.54 (0.32, 0.92) 0.021
 No IRIS diagnosis Referent Referent
Age (years)
 ≥40 1.57 (1.23, 2.01) <0.001 1.58 (1.23, 2.03) <0.001
 <40 Referent Referent
Sex
 Female 0.91 (0.67, 1.25) 0.57 0.96 (0.69, 1.34) 0.82
 Male Referent Referent
Race
 All other 1.31 (1.03, 1.67) 0.030 1.0 (0.8, 1.3) 0.95
 White, non-Hispanic Referent Referent
HIV risk
 IDU 2.11 (1.55, 2.85) <0.001 1.41 (1.02, 1.94) 0.038
 MSM/HRH/other Referent Referent
HIV viral load (log10 copies/ml)
a
 ≥5 2.01 (1.56, 2.56) <0.001 1.54 (1.19, 2.00) 0.001
 <5 Referent Referent
CD4 cell count (cells/μl)
a
 <50 6.93 (4.64, 10.33) <0.001 3.89 (2.49, 6.09) <0.001
 50–200 2.30 (1.49, 3.55) <0.001 1.51 (0.96, 2.38) 0.073
 200–350 1.23 (0.75, 2.02) 0.42 1.03 (0.62, 1.71) 0.91
 Missing 4.61 (2.83, 7.50) <0.001 3.05 (1.84, 5.05) <0.001
 ≥350 Referent Referent
Year of first qualifying cART
 1996–2000 1.98 (1.41, 2.78) <0.001 1.78 (1.26, 2.52) 0.001
 2001–2008 Referent Referent
Nadir CD4 cell count (cells/μl)
 <200 3.30 (2.44, 4.45) <0.001
 ≥200 Referent
AIDS OI diagnosis at baseline
b
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Baseline factor
Univariate analysis
HR (95% CI) P value
Adjusted analysis
HR (95% CI) P value
 AIDS OI at baseline 3.22 (2.52, 4.10) <0.001 1.58 (1.21, 2.05) <0.001
 No AIDS OI at baseline Referent
Insurance
 Public or other insurance 1.98 (1.54, 2.54) <0.001 1.45 (1.11, 1.90) 0.007
 Private Referent Referent
Prior antiretroviral exposure
 Yes 3.21 (2.17, 4.74) <0.001 2.80 (1.88, 4.18) <0.001
 No Referent Referent
cART, combination antiretroviral therapy; CI, confidence interval; HR, hazard ratio; HRH, high-risk heterosexual; IRIS, immune reconstitution 
inflammatory syndrome; OI, opportunistic infection.
a
Viral loads and CD4 values closest to the start of a new or different cART within the preceding 180 days.
b
OI prior to the start of a new or different cART.
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